Abstract ID: 26-371
Clinical Outcomes of Teprotumumab in Thyroid Eye Disease: A Case Series from Brazil
Author: Ana Karina Teles Silveira Base Hospital / Institution: Hospital das Clínicas – Universidade Federal de Pernambuco
Presentation Type: ePoster Presentation
Purpose
Brazil was the second country to approve teprotumumab for TED treatment. We report the first four cases treated in northeastern Brazil. Thyroid eye disease (TED) is an autoimmune inflammatory disorder characterized by proptosis, diplopia, eyelid retraction, and orbital inflammation, often leading to significant functional and cosmetic impairment. Teprotumumab, a monoclonal antibody targeting the insulin-like growth factor-1 receptor, has emerged as a novel disease-modifying therapy for moderate-to-severe TED. This retrospective case series evaluated four patients with TED treated with teprotumumab at a referral center in Brazil. Clinical and imaging findings were reviewed longitudinally. At the time of analysis, two patients had completed therapy and two remained under treatment. Assessed parameters included best-corrected visual acuity, Clinical Activity Score (CAS), eyelid retraction, diplopia, Hertel exophthalmometry, intraocular pressure, and orbital magnetic resonance imaging findings. Marked clinical improvement was observed following treatment. Two patients demonstrated significant reduction in eyelid retraction and proptosis, with reductions greater than 3 mm in one eye. Orbital MRI revealed decreased enlargement of extraocular muscles, particularly the superior and medial rectus muscles, with reductions exceeding 5 mm. Improvement in diplopia and CAS reflected reduced inflammatory activity. One patient with ocular hypertension previously requiring multiple hypotensive medications experienced intraocular pressure reduction and no longer required therapy. Best-corrected visual acuity improved in three of the four patients during follow-up. Overall, both clinical and radiologic findings consistently demonstrated a favorable therapeutic response. These findings reinforce the role of teprotumumab as an effective disease-modifying therapy for TED, promoting functional, anatomical, and inflammatory improvement.
Methods
CASE SERIES
Results
CASE SERIES
Conclusion
CASE SERIES
Additional Authors
| First name | Last name | Base Hospital / Institution |
|---|---|---|
| Divar Fernandes | Pires Neto | Hospital das Clínicas – Universidade Federal de Pernambuco |
| Maria Carolina | Batista Figueroa | Hospital das Clínicas – Universidade Federal de Pernambuco |
| Gabriela Porto | Barreto | Hospital das Clínicas – Universidade Federal de Pernambuco |